InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Australia: Court upholds patents to isolated genes




The Full Federal Court, in D'Arcy v Myriad Genetics Inc, has unanimously decided to specifically diverge from the opinions of the US Supreme Court in the corresponding US Myriad case, in holding that isolated genetic/biological material can be patentable subject matter.

The patent claims related to isolated nucleic acids encoding mutant or polymorphic BRCA 1 polypeptides, which are linked to breast and ovarian cancer. The appellant argued that such claims were not to patentable subject matter.

The Court considered a number of factors, including that patent boundaries must continually develop with society, human intervention to create an artificial state of affairs is essential, and expressions such as "work of nature" are unhelpful in deciding these issues. A further factor was that the legislature had failed to enact any restrictive legislation in the area despite a number of inquries.

The Court stated that the unique chemical and physical makeup of an isolated nucleic acid rendered it not only artificial but also different from its natural counterpart and the isolation of a nucleic acid led to an economically useful result – in this case, the treatment of breast and ovarian cancers.

The Federal Court stated "with respect, the Supreme Court's emphasis on the similarity of 'the location and order of the nucleotides' existing within the nucleic acid in nature before Myriad found them is misplaced. It is the chemical changes in the isolated nucleic acid which are of critical importance, as this is what distinguishes the product as artificial and economically useful". The Court's view was that "following Chakrabarty and NRDC, the isolated nucleic acid has 'markedly different characteristics from any found in nature'; Myriad did not merely 'separate that gene from its surrounding genetic material'. Myriad's claim, properly considered is not, as the US Supreme Court considered, concerned 'primarily with the information contained in the genetic sequence [rather than] with the specific chemical composition of a particular molecule'".

Ultimately, it was found that the isolated nucleic acid had resulted in an artificially created state of affairs for economic benefit which was patent eligible subject matter.

Peter Treloar

Shelston IP
Level 21, 60 Margaret Street
Sydney NSW 2000, Australia
Tel: +61 2 9777 1111
Fax: +61 2 9241 4666
email@shelstonip.com
www.shelstonip.com


Comments






profile

Managing IP

ManagingIP

ManagingIP profile

Federal Circuit’s Brunetti ruling: barring immoral or scandalous marks is unconstitutional restriction of free spee… https://t.co/MivCKFINHg

Dec 15 2017 10:12 ·  reply ·  retweet ·  favourite
ManagingIP profile

Federal Circuit rules in Amgen v Sandoz on remand from SCOTUS https://t.co/uYIkfVhCHG https://t.co/2OZAscsz32

Dec 14 2017 09:58 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @mdloney: Canada moves closer to joining the Hague Agreement with the release of proposed new Industrial Design Regulations https://t.co

Dec 12 2017 10:22 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null null null

null null null

End of Year 2017

Tribal sovereign immunity: Taking a wrecking ball to the IPR system

The lawyer behind Allergan’s controversial transfer of patents to a Native American tribe says others are “lining up to do deals”. But, Michael Loney asks, will the PTAB rule that sovereign immunity applies in these types of deals?



Most read articles

Supplements